Edwards LifesciencesXSWX:EW +0.37%97 Buyback Yield % is 2.05 as of Jun. 26, 2026, which is 2% above its 10-year median of 2.00. GuruFocus rates XSWX:EW with a GF Score™ of 97/100 and a GF Value™ of CHF75.73. The stock has 5 warning signs investors should review. Among 346 Medical Devices & Instruments companies, Edwards Lifesciences ranks better than 86.99% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Edwards Lifesciences Buyback Yield % Related Terms
Edwards Lifesciences Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:EW vs DXCM, GEHC, BSX: Buyback Yield % Comparison
For the Medical Devices subindustry, Edwards Lifesciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences (XSWX:EW) has a Buyback Yield % of 2.05 as of Jun. 26, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Edwards Lifesciences and its competitors. This is near median its historical median of 2.00. Over the past decade, Edwards Lifesciences' Buyback Yield % has ranged from 0.54 to 3.87. According to the industry distribution chart, Edwards Lifesciences ranks #45 out of 346 companies in the Medical Devices & Instruments industry, placing it in the top 13%.
Is Edwards Lifesciences' Buyback Yield % too high?
Edwards Lifesciences' current Buyback Yield % of 2.05 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 3.87. Based on the distribution chart, Edwards Lifesciences ranks #45 out of 346 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Edwards Lifesciences has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Buyback Yield % compare to DXCM and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #45 out of 346 companies for Buyback Yield %. This places Edwards Lifesciences in the top 13% of its industry — outperforming the majority of peers. Historically, Edwards Lifesciences' own Buyback Yield % has ranged from 0.54 to 3.87 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Buyback Yield % is 2.05, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current Buyback Yield % of 2.05. The stock's GF Value™ is CHF75.73, compared to a current price of CHF72.91 — trading 3.7% below its estimated fair value. The current Buyback Yield % is 2.05, which is near median its 10-year median of 2.00. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current Buyback Yield % is 2.05 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of CHF72.91 is trading 3.7% below its estimated GF Value™ of CHF75.73.
Key valuation signals for XSWX:EW:
Buyback Yield %: 2.05 (near median its 10-year median of 2.00)
GF Value™: CHF75.73 vs. price of CHF72.91 (3.7% below fair value)
No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score
Get the complete analysis for XSWX:EW
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EW has been successfully added to your 
